In the realm of women's health, vaginal and vulvar cancers represent a formidable challenge, often overshadowed by more common and better-understood diseases. The stark reality is that the five-year relative survival rates for these cancers (53% and 74%, respectively) are significantly lower than those for breast (93%) and endometrial (84%) cancers. This disparity is not merely a statistical anomaly but a call to action, urging us to delve deeper into the complexities of prevention, diagnosis, and treatment. The rarity of these cancers, with only 117 new cases of vaginal cancers and 401 new cases of vulvar cancers diagnosed in Australia in 2025, contributes to the challenge. This scarcity means that clinicians may rarely encounter these conditions, making it difficult to stay abreast of the latest diagnostic and management strategies. Moreover, the lack of specific symptoms and early detection screening tests further complicates the diagnostic process. The situation is particularly dire when we consider the existing guidelines for these cancers. A systematic review of international guidelines revealed that while 45 guidelines were identified, only two were developed in Australia, and both were published over a decade ago. The review also highlighted a disparity in focus, with 62% of the guidelines addressing vulvar cancer and only 22% focusing on vaginal cancer. This imbalance underscores the need for more comprehensive and up-to-date guidelines tailored to the unique challenges posed by these cancers. The review identified consistent recommendations for prevention and early detection, including HPV vaccination, opportunistic cervical screening, and biopsy for lesions that do not resolve or are suspected to be invasive. For diagnosis, the importance of taking a patient's medical history, conducting a physical evaluation, and performing cytology testing (plus HPV testing) and blood tests was emphasized. Referral to health professionals and further investigations for persistent symptoms were also highlighted. However, the guidelines fell short in several critical areas. Firstly, the views and preferences of consumers, particularly those from priority groups like Aboriginal and Torres Strait Islander people, people living in rural and remote areas, and older Australians, were not adequately incorporated. This omission raises concerns about the equity and accessibility of the guidelines. Secondly, the guidelines were rated low in terms of applicability, lacking practical advice on implementation, resource implications, and methods for monitoring guideline uptake. This limitation hampers the ability to translate the recommendations into real-world clinical practice. The development of an Optimal Care Pathway (OCP) for vaginal and vulvar cancers in Australia could address these shortcomings. OCPs have proven effective in improving survival rates for common cancers like colorectal cancer, independent of new diagnostic tests or treatments, lower disease stage at diagnosis, and lower likelihood of emergency surgery. By combining existing evidence and expert opinion, OCPs can provide clear, standardized pathways for prevention and detection, supporting general practitioners in clinical practice. However, the current screening practices, such as the National Cervical Screening Program, should be evaluated to ensure that they do not limit opportunities for incidental findings during physical exams. The development of an OCP for vaginal and vulvar cancers should also consider the impact of self-collection for HPV screening on HPV-independent cases identified through visual inspection. In conclusion, the prevention and diagnosis of vaginal and vulvar cancers demand a multifaceted approach that addresses the unique challenges posed by these rare diseases. By developing comprehensive, up-to-date guidelines and implementing Optimal Care Pathways, we can improve clinical assessment, prevent and diagnose these cancers, and ultimately enhance the survival rates for women affected by these diseases. Personally, I believe that the development of an OCP for vaginal and vulvar cancers is not just a medical necessity but a moral imperative. It represents a commitment to ensuring that no woman, regardless of her background or location, is left behind in the fight against these devastating diseases. The journey towards better prevention, diagnosis, and treatment for vaginal and vulvar cancers is a collective effort that requires the collaboration of healthcare professionals, researchers, policymakers, and consumers. By working together, we can make significant strides in improving the outcomes for women affected by these cancers and ultimately save lives.
